FOLD News Alert Amicus Therapeutics (FOLD) 7.73 12/16/2014 2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amicus Therapeutics (FOLD) 7.73 $FOLD

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), FPRX: 21.92 (+0.07), ZFGN: 21.67 (-0.08), CRIS: 1.15 (-0.01), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), ZGNX: 1.11 (-0.03), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), NDAQ: 45.74 (-0.72), FPRX: 21.92 (+0.07), CRIS: 1.15 (-0.01), ZFGN: 21.67 (-0.08), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 3.67 (+0.08), GEVA: 87.38 (+0.27), SGMO: 14.33 (-0.41), FOLD: 7.73 (-0.15), CUR: 2.37 (-0.02)

This Tiny Biotech Worries Sanofi and Shire, and Vexes GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 8:28AM CST
Source: Amicus Therapeutics. Doctors may soon have a new therapy to use when treating patients with Fabry Disease, a rare genetic disease that can result in kidney failure. That's because emerging biotech stock Amicus Therapeutics plans to file...
SHPG: 208.76 (+0.28), GSK: 41.92 (+0.62), SNY: 45.38 (+0.98), FOLD: 7.73 (-0.15)

Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry Disease
GlobeNewswire - Thu Dec 11, 6:30AM CST
Successful Pre-Submission Meeting with European Medicines Agency Completed
FOLD: 7.73 (-0.15)

Amicus Therapeutics Has Returned 30.9% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Dec 10, 9:12AM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 3 weeks, Amicus Therapeutics has returned 30.92% as of today's recent price of $8.72.
FOLD: 7.73 (-0.15)

3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user  Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 325.13 (-10.67), ISIS: 54.94 (-1.99), OMED: 18.77 (+0.36), GILD: 100.46 (-2.70), TEVA: 55.15 (-0.47), EPZM: 16.68 (-0.82), AGIO: 107.47 (-3.76), SNY: 45.38 (+0.98), FOLD: 7.73 (-0.15), XLRN: 37.63 (-0.37), NVS: 91.65 (+0.01), CELG: 110.09 (-1.79)

Amicus Therapeutics to Present at Oppenheimer Healthcare Conference
GlobeNewswire - Thu Dec 04, 3:04PM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the 25th Annual Oppenheimer Healthcare Conference in New York, NY on Thursday, December 11, 2014 at 1:35 p.m. ET.
FOLD: 7.73 (-0.15)

Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 54.94 (-1.99), OPK: 8.70 (-0.16), ISR: 1.50 (-0.02), FOLD: 7.73 (-0.15), NSPH: 0.37 (+0.02)

Fabry Disease - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/sgtssl/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fabry Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amicus Therapeutics - Biosidus - Genzyme Corporation - greenovation Biotech GmbH - iBio - ISU ABXIS - JCR Pharmaceuticals - Neuraltus Pharmaceuticals - Pharming Group - Protalix BioTherapeutics For more information visit http://www.researchandmarkets.com/research/sg...ry_disease
FOLD: 7.73 (-0.15)

16.2% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Tue Dec 02, 5:03PM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 2 weeks, Amicus Therapeutics has returned 16.22% as of today's recent price of $7.74.
FOLD: 7.73 (-0.15)

Will Amicus Therapeutics (FOLD) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:41AM CST
Will Amicus Therapeutics (FOLD) Continue to Surge Higher?
FOLD: 7.73 (-0.15)

Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 8.25 (+0.21), KNMD: (), OPK: 8.70 (-0.16), PFE: 30.67 (-0.19), AZN: 69.56 (-0.18), GSK: 41.92 (+0.62), FOLD: 7.73 (-0.15), NVS: 91.65 (+0.01)

Amicus Therapeutics (FOLD) Weak On High Volume
at The Street - Mon Dec 01, 9:00AM CST
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a weak on high relative volume candidate
FOLD: 7.73 (-0.15)

Amicus Therapeutics anticipates gross proceeds of USD103.5m from public offering, including underwriters option
M2 - Wed Nov 26, 6:59AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) said on Tuesday that it has closed its public offering, including the underwriters full exercise of their option to purchase an additional 2,077,500 shares.
FOLD: 7.73 (-0.15)

5 Stocks With Big Insider Buying: Hertz Global and More
at The Street - Wed Nov 26, 5:00AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
CJES: 11.91 (+0.15), HTZ: 20.79 (-0.71), STAA: 9.21 (+0.25), JCP: 6.32 (-0.09), FOLD: 7.73 (-0.15)

InsiderInsights.com Daily Round Up 11/25/14: AAPL, FCF, AVID, SC
InsiderInsights - at Seeking Alpha - Wed Nov 26, 12:20AM CST

SC: 17.76 (+0.04), ACMP: 50.78 (+0.04), NEOT: 7.45 (+0.04), BBY: 35.77 (-1.14), SGM: 12.28 (+0.62), FIVE: 38.17 (-0.87), AVID: 13.59 (-0.51), FCF: 8.60 (+0.09), SPW: 77.79 (-0.75), NLNK: 33.10 (-0.36), AINC: 87.10 (+3.18), PF: 34.21 (-0.11), AAPL: 106.75 (-1.47), SFXE: 3.82 (+0.09), INTU: 92.11 (-0.56), CSCO: 26.58 (-0.10), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option
GlobeNewswire - Mon Nov 24, 3:00PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,077,500 shares of common stock. As a result, the Company issued a total of 15,927,500 shares in the offering at a price of $6.50 per share.
JPM: 58.43 (-0.73), FOLD: 7.73 (-0.15)

Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 37.78 (-0.52), FATE: 3.67 (+0.08), CNDO: 2.05 (+0.05), RCPT: 114.46 (-0.67), FOLD: 7.73 (-0.15)

BioMarin Buys Prosensa Backs Up Troubled Drug
at Investor's Business Daily - Mon Nov 24, 9:22AM CST
Biotech BioMarin Pharmaceutical (BMRN) agreed Monday to pay $680 million in cash for Prosensa Holding, developer of a muscular-dystrophy drug with a checkered history. Prosensa soared 63%, while BioMarin slipped a fraction in early trading in the...
BMRN: 86.06 (-1.17), RNA: 18.55 (+0.24), SRPT: 12.60 (-0.40), GSK: 41.92 (+0.62), FOLD: 7.73 (-0.15)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 53

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 141

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 163

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 82

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 38

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 91

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Prostate Treatment Program Launches in Dallas

Updated Category News Views 191

Transforming Prostate Care with the TULSA Program The landscape of prostate treatment is evolving, thanks to the groundbreaking advancements brought forth by Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) and its launch of the TULSA program in collaboration with Texas Prostate and Dallas Medical Center. This pioneering initiative aims to cater to the rising need for...

Continue Reading
Addex Expands Share Capital for Future Financial Flexibility

Updated Category News Views 254

Recent Developments at Addex Therapeutics Ad Hoc Announcement Addex Therapeutics, a clinical-stage biopharmaceutical firm, has made a significant move by issuing 34,300,000 new registered shares. These shares, issued by Addex Pharma S.A, a wholly-owned subsidiary, allow the company to strategically increase its issued share capital to CHF 2,186,544.96. This adjustment...

Continue Reading
Jasper Therapeutics Receives Major Boost from Oppenheimer's $80 Target

Updated Category News Views 130

Oppenheimer Affirms Positive Outlook for Jasper Therapeutics Jasper Therapeutics (NASDAQ:JSPR) has recently captured the attention of investors, particularly following Oppenheimer's announcement of its continued support with an Outperform rating and a notable price target set at $80. The positive sentiment originates from the recent findings of a Phase 1b/2a clinical...

Continue Reading
Taylor Morrison Launches New Resort Community Near Jacksonville

Updated Category News Views 286

Taylor Morrison Launches New Resort Community Near Jacksonville In an exciting development for homebuyers, Taylor Morrison, recognized as one of America’s Most Trusted® Home Builders, has officially broken ground on its first resort lifestyle community in the Jacksonville area. This ambitious project, named Esplanade at St. Marys, spans an impressive 1,250 acres and is...

Continue Reading
Middlefield Canadian Income PCC Report: NAV Insights

Updated Category News Views 123

Understanding Middlefield Canadian Income PCC's Financial Position Middlefield Canadian Income PCC is a notable player in the investment landscape, focusing on generating sustainable income from a diversified portfolio. Understanding its net asset value (NAV) is crucial for investors looking to gauge the company's financial stability and growth potential. Current Net...

Continue Reading